(Q42980410)

12 November 2017

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

18

1 reference

12 November 2017

Dusheiko G

1

1 reference

12 November 2017

Main J

2

1 reference

12 November 2017

Thomas H

3

1 reference

12 November 2017

Reichard O

4

1 reference

12 November 2017

Lee C

5

1 reference

12 November 2017

Dhillon A

6

1 reference

12 November 2017

Rassam S

7

1 reference

12 November 2017

Fryden A

8

1 reference

12 November 2017

Reesink H

9

1 reference

12 November 2017

Bassendine M

10

1 reference

12 November 2017

Norkrans G

11

1 reference

12 November 2017

Cuypers T

12

1 reference

12 November 2017

Lelie N

13

1 reference

12 November 2017

Telfer P

14

1 reference

12 November 2017

Watson J

15

1 reference

12 November 2017

Weegink C

16

1 reference

12 November 2017

Sillikens P

17

1 reference

12 November 2017

1 November 1996

1 reference

12 November 2017

Journal of Hepatology

1 reference

12 November 2017

25

1 reference

12 November 2017

591-598

1 reference

12 November 2017

5

1 reference

Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Sequence variability of hepatitis C virus and its clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

HCV genotypes in chronic hepatitis C and response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980225-X

7 January 2021

10.1016/S0168-8278(96)80225-X

Identifiers

DOI

1 reference

12 November 2017

1 reference